Characterization of a new heteropolysaccharide from green guava and its application as an α-glucosidase inhibitor for the treatment of type II diabetes,Food & Function

当前位置： X-MOL 学术 › Food Funct. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Characterization of a new heteropolysaccharide from green guava and its application as an α-glucosidase inhibitor for the treatment of type II diabetes
Food & Function ( IF 6.1 ) Pub Date : 2018-06-28 00:00:00 , DOI: 10.1039/c8fo00790j
Yukun Jiao _{1,

2,

3,

4,

5} , Dehong Hua _{1,

2,

3,

4} , Dong Huang _{1,

2,

3,

4} , Qian Zhang _{5,

6} , Chunyan Yan _{1,

2,

3,

4}

Affiliation

Psidium guajava fruit is a subtropical fruit, functional food and traditional medicine for the adjuvant treatment of diabetes mellitus in China. To investigate the active components responsible for its health benefits, a novel heteropolysaccharide GP70-3 was purified by water extraction, ethanol precipitation and column chromatography. Structural characterization of GP70-3 was elucidated for the first time by monosaccharide composition assay, Fourier transform-infrared spectroscopy (FT-IR), methylation analysis, gas chromatography coupled with mass spectrometry (GC-MS) and nuclear magnetic resonance spectroscopy (NMR). The data revealed that GP70-3 contained a backbone of 1→3,6)-linked β-D-Galp, 1→5)-linked α-L-Araf, 1→6)-linked β-D-Galp and 1→3)-linked β-D-Galp, branched with 1→2,3,5)-linked α-L-Araf, 1→3)-linked α-L-Araf, 1→3)-linked α-L-Rhap, 1→3)-linked β-D-GlcpA, 1→3)-linked β-D-GalpA and terminated with →1)-linked β-D-Galp. Advanced structure studies showed GP70-3 consisted of irregular flakes with rounded-spherical pores. Moreover, GP70-3 exhibited outstanding α-glucosidase inhibitory activity in vitro, with an IC₅₀ value of 2.539 ± 0.144 μM, which was 1867 times higher than that of the positive control acarbose (IC₅₀ value of 4.744 ± 0.026 mM). Therefore, consumption of guava polysaccharides may be beneficial as an α-glucosidase inhibitor for reducing the postprandial blood glucose level and treating type II diabetes.

更新日期：2018-06-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>